Peter M. Andersen

29.0k total citations · 4 hit papers
225 papers, 12.9k citations indexed

About

Peter M. Andersen is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Peter M. Andersen has authored 225 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 195 papers in Neurology, 112 papers in Genetics and 49 papers in Molecular Biology. Recurrent topics in Peter M. Andersen's work include Amyotrophic Lateral Sclerosis Research (193 papers), Neurogenetic and Muscular Disorders Research (112 papers) and Parkinson's Disease Mechanisms and Treatments (67 papers). Peter M. Andersen is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (193 papers), Neurogenetic and Muscular Disorders Research (112 papers) and Parkinson's Disease Mechanisms and Treatments (67 papers). Peter M. Andersen collaborates with scholars based in Sweden, Germany and United States. Peter M. Andersen's co-authors include Stefan L. Marklund, Ammar Al‐Chalabi, Thomas Brännström, P. Andreas Jonsson, Karin S. Graffmo, Karin Forsberg, Orla Hardiman, Mikael Oliveberg, John Powell and Markus Weber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Peter M. Andersen

217 papers receiving 12.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force

2011 788 citations Peter M. Andersen, Mamede de Carvalho et al. European Journal of Neurology profile →
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis

2006 518 citations Peter M. Andersen, Orla Hardiman et al. profile →
Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

2011 506 citations Peter M. Andersen, Ammar Al‐Chalabi profile →
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)

2024 43 citations Philip Van Damme, Ammar Al‐Chalabi et al. European Journal of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter M. Andersen Sweden	61	9.7k	5.4k	3.7k	2.2k	1.6k	225	12.9k
Vincent Meininger France	62	10.3k 1.1×	5.8k 1.1×	3.7k 1.0×	2.2k 1.0×	1.7k 1.1×	213	14.1k
P. Nigel Leigh United Kingdom	57	9.6k 1.0×	4.4k 0.8×	3.1k 0.9×	1.9k 0.9×	2.1k 1.4×	167	12.9k
Martin R. Turner United Kingdom	63	10.7k 1.1×	4.9k 0.9×	3.1k 0.8×	2.2k 1.0×	2.2k 1.4×	262	14.2k
Lucette Lacomblez France	47	7.0k 0.7×	3.6k 0.7×	2.4k 0.6×	1.4k 0.7×	1.6k 1.0×	154	10.3k
Ammar Al‐Chalabi United Kingdom	64	14.8k 1.5×	8.2k 1.5×	5.5k 1.5×	3.3k 1.5×	2.6k 1.7×	270	18.2k
Leo McCluskey United States	44	8.0k 0.8×	3.3k 0.6×	3.4k 0.9×	1.9k 0.9×	2.8k 1.8×	90	11.0k
Leonard H. van den Berg Netherlands	62	8.9k 0.9×	4.3k 0.8×	3.3k 0.9×	1.5k 0.7×	1.7k 1.1×	260	12.9k
Vincenzo Silani Italy	55	7.8k 0.8×	4.5k 0.8×	4.4k 1.2×	1.3k 0.6×	1.5k 0.9×	369	12.9k
Orla Hardiman Ireland	74	19.2k 2.0×	9.9k 1.8×	5.0k 1.4×	3.4k 1.5×	3.2k 2.1×	382	24.2k
Michael J. Strong Canada	55	7.3k 0.7×	3.6k 0.7×	3.1k 0.9×	1.5k 0.7×	2.1k 1.3×	214	10.6k

Countries citing papers authored by Peter M. Andersen

Since Specialization

Citations

This map shows the geographic impact of Peter M. Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Andersen more than expected).

Fields of papers citing papers by Peter M. Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Andersen. The network helps show where Peter M. Andersen may publish in the future.

Co-authorship network of co-authors of Peter M. Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Andersen. A scholar is included among the top collaborators of Peter M. Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Andersen. Peter M. Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonsson, P. Andreas, Karin Forsberg, Peter M. Andersen, et al.. (2025). SOD1 Protein Content in Human Central Nervous System and Peripheral Tissues. Journal of Neurochemistry. 169(6). e70136–e70136.

Coté, Atina G., Haotian Zhang, Jochen Weile, et al.. (2025). Landscapes of missense variant impact for human superoxide dismutase 1. The American Journal of Human Genetics. 112(10). 2295–2315.

Damme, Philip Van, Ammar Al‐Chalabi, Peter M. Andersen, et al.. (2024). European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD). European Journal of Neurology. 31(6). e16264–e16264. 43 indexed citations breakdown →

Weishaupt, Jochen H., Peter Körtvélyessy, Ute Weyen, et al.. (2024). Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients. SHILAP Revista de lepidopterología. 4(1). 150–150. 11 indexed citations

Freischmidt, Axel, Anika M. Helferich, Albert C. Ludolph, et al.. (2024). Upregulated miR-10b-5p as a potential miRNA signature in amyotrophic lateral sclerosis patients. Frontiers in Cellular Neuroscience. 18. 1457704–1457704.

Zimyanin, Vitaly, Hannes Glaß, Julia Japtok, et al.. (2023). Live Cell Imaging of ATP Levels Reveals Metabolic Compartmentalization within Motoneurons and Early Metabolic Changes in FUS ALS Motoneurons. Cells. 12(10). 1352–1352. 3 indexed citations

Ludolph, Albert C., Ingo Uttner, Natalia Szejko, et al.. (2023). Determining impairment in the Swedish, Polish and German ECAS: the importance of adjusting for age and education. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(5-6). 475–484. 2 indexed citations

Lulé, Dorothée, et al.. (2023). Quality of life and depression in patients with amyotrophic lateral sclerosis – does the country of origin matter?. BMC Palliative Care. 22(1). 72–72. 2 indexed citations

Osmanovic, Alma, Helge Martens, Kathrin Müller, et al.. (2021). Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients. Genes. 13(1). 84–84. 7 indexed citations

10.

Salmon, Kristiana, Matthew C. Kiernan, Seung Hyun Kim, et al.. (2021). The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 145(4). 1207–1210. 24 indexed citations

11.

Lulé, Dorothée, Hans‐Peter Müller, Patrick Weydt, et al.. (2020). Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers—a developmental disorder. Journal of Neurology Neurosurgery & Psychiatry. 91(11). 1195–1200. 52 indexed citations

12.

Kuźma‐Kozakiewicz, Magdalena, et al.. (2019). An observational study on quality of life and preferences to sustain life in locked-in state. Neurology. 93(10). e938–e945. 43 indexed citations

13.

Zhu, Shaochun, Anna Wuolikainen, Junfang Wu, et al.. (2019). Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS. Journal of Molecular Neuroscience. 69(4). 643–657. 37 indexed citations

14.

Benatar, Michael, Joanne Wuu, Peter M. Andersen, et al.. (2018). Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 90(7). e565–e574. 101 indexed citations

15.

Czell, David, Peter M. Andersen, Christoph Neuwirth, Mitsuya Morita, & Markus Weber. (2013). Progressive aphasia as the presenting symptom in a patient with amyotrophic lateral sclerosis with a novel mutation in the OPTN gene. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(2). 138–140. 10 indexed citations

16.

Liu, Jing‐Xia, Thomas Brännström, Peter M. Andersen, & Fátima Pedrosa Domellöf. (2011). Different Impact of ALS on Laminin Isoforms in Human Extraocular Muscles versus Limb Muscles. Investigative Ophthalmology & Visual Science. 52(7). 4842–4842. 19 indexed citations

17.

Bergemalm, Daniel, Karin Forsberg, Vaibhav Srivastava, et al.. (2010). Superoxide dismutase‐1 and other proteins in inclusions from transgenic amyotrophic lateral sclerosis model mice. Journal of Neurochemistry. 114(2). 408–418. 37 indexed citations

18.

Czapliński, Adam, Andreas Steck, Peter M. Andersen, & Markus Weber. (2004). Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis. European Journal of Neurology. 11(8). 567–568. 16 indexed citations

19.

Powell, John, et al.. (2001). Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Annals of Neurology. 49(5). 643–649. 54 indexed citations

20.

Udd, Bjarne, Vesa Juvonen, Peter M. Andersen, et al.. (2000). Founder effect in spinal and bulbar muscular atrophy (SBMA) in Scandinavia. European Journal of Human Genetics. 8(8). 631–636. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact